Skip to content

Comparison of Remifentanil-induced Postoperative Hyperalgesia Between Patients From Plain Area and Plateau Area

Comparison of Remifentanil-induced Postoperative Hyperalgesia After Gynecological Laparoscopic Surgery Between Patients From the Plain Area and the Plateau Area

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05028049
Enrollment
160
Registered
2021-08-31
Start date
2021-08-30
Completion date
2021-12-31
Last updated
2021-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Anesthesia

Keywords

Remifentanil, Opioid-induced hyperalgesia, Postoperative pain, pain intensity

Brief summary

Purpose: 1. To compare the incidence of postoperative hyperalgesia induced by remifentanil in patients undergoing gynecological laparoscopic surgery in plateau and plain areas 2. To compare the peri-operative analgesic requirements of patients in plain and plateau areas

Detailed description

Our research group has been committed to the research of remifentanil-induced hyperalgesia for a long time. In the previous study, it was found that intraoperative infusion of remifentanil (0.3ug/kg•min) \>1h can lead to remifentanil-induced hyperalgesia and the incidence rate is relative high in the plain area. Due to the long-term low pressure and hypoxia of people living in plateau areas, a series of changes will occur in the respiratory and circulatory systems, and their anesthesia management needs to be adjusted accordingly. However, there is no relevant research on whether or not hyperalgesia occurs in people in plateau areas (altitude level \>3000 meters). Therefore, this study hopes to compare the incidence and degree of remifentanil-induced hyperalgesia after gynecological laparoscopic surgery in plain areas and plateau areas.

Interventions

Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia

Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia

OTHERplain areas

Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)

OTHERplateau areas

Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)

Sponsors

Tianjin Medical University General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is scheduled to undergo gynecological laparoscopic surgery under a short general anesthesia of less than 2 hours 2. Subject's American Society of Anesthesiologists physical status is I-II. 3. The subject's parent/legally authorized guardian has given written informed consent to participate. 4. Patients in plateau areas are long staying residents in above 3000 meters above sea level for enrollment, while patients in plain areas are long staying residents below 1000 meters above sea level.

Exclusion criteria

1. Subject has a diagnosis of renal or liver failure. 2. Subject has a diagnosis of Insulin dependent diabetes. 3. Subject is allergy and contraindication to any drugs used during general anesthesia. 4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre-existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery. 5. Subject has any contraindication for the use of patient-controlled analgesia (PCA). 6. Subject is pregnant or breast-feeding. 7. Subject is obese (body mass index \>30kg/m2).

Design outcomes

Primary

MeasureTime frameDescription
Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm48 hours after surgeryThe mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament after surgery

Secondary

MeasureTime frameDescription
Normalized Area of Hyperalgesia Around the Incision48 hours after surgeryThe skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.
Mechanical hyperalgesia threshold around the incision48 hours after surgeryThe mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament.
Time of First Postoperative Analgesic Requirement1 hour after surgeryFirst postoperative pain (NRS≥5) is initially controlled by titration of Hydromorphone.
Pain Score (NRS)48 hours after surgeryThe pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10= greatest imaginable pain.
Cumulative Hydromorphone Consumption48 hours after surgeryEach patient was administered analgesics using a PCA (Patient-controlled analgesia) pump containing Hydromorphone (200μg) in normal saline at a total volume of 100 ml after leaving PACU (Postanesthesia care unit). This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Hydromorphone cumulative consumption is recorded 48 hours postoperatively
Occurrence of Side Effects48 hours after surgeryOccurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus
Total Dose of First Postoperative Analgesic Requirement1 hour after surgeryFirst postoperative pain (NRS≥5) is initially controlled by titration of Hydromorphone.

Countries

China

Contacts

Primary ContactGuolin Wang, MD
wangguolinghad@hotmail.com+8618604755166

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026